Christina M Dieli-Conwright
University of Southern California, USA
Posters & Accepted Abstracts: J Metabolic Synd
Metabolic dysregulation (MetD), defined here as metabolic syndrome (MSY), insulin resistance (IR), and visceral adiposity (VA), is a long-term complication of curative treatment for many cancers including breast, prostate, and testicular. MetD in breast cancer survivors (BCS) is a serious concern during cancer survivorship that if treated may improve survivorship and further prevent cancer recurrence. MetD, due to heightened adipose and systemic inflammation, and increased cell proliferation, may influence one�s risk for cancer recurrence and mortality. BCS represent a distinctive group who endure many treatment-associated alterations in lifestyle habits including weight gain, reduced physical activity levels, and worsening metabolic profiles leading to MetD. Obesity at breast cancer diagnosis related markers of MetD including MSY and IR at diagnosis, and hyperinsulinemia post-treatment, are associated with increased risk of breast cancer mortality, all-cause mortality, and breast cancer recurrence. Given these facts, determination of effective exercise interventions for reducing MetD in BCS is a much needed area of research. Exercise may be an effective intervention for attenuating MetD, thereby reducing risk for additional associated chronic diseases. Since lifestyle factors such as exercise and dietary intake affect the risk of developing MetD, it is important, possibly preferable, to target lifestyle factors to prevent/manage MetD in BCS, particularly due to the fact that cancer survivors have undergone the physiologic burden of other cancer-related pharmacologic treatments with varying side effects. The purpose of this symposium will be to discuss the impact of MetD on cancer-related outcomes and the utilization of exercise to target MetD in obese BCS.
Email: cdieli@usc.edu
Journal of Metabolic Syndrome received 48 citations as per Google Scholar report